Why is Piramal Pharma Ltd falling/rising?

Recent Price Movement and Market Context

The stock has been under pressure for the past week, declining 5.55% compared to the Sensex’s 2.55% fall over the same period. Year-to-date, the stock is down 2.15%, slightly worse than the benchmark’s 1.93% decline. Over the last year, the stock has significantly underperformed, plunging 28.89% while the Sensex gained 7.67%. Despite a positive three-year return of 47.76%, outperforming the Sensex’s 37.58%, the recent trend is decidedly negative.

On the day in question, the stock touched an intraday low of ₹168, nearly 2.11% above its 52-week low of ₹165.05, signalling proximity to its lowest price point in a year. It has also underperformed its sector by 1.4% today and has been falling for two consecutive days, losing 6.77% in that span. The stock is trading below all key moving averages—5-day, 20-day, 50-day, 100-day, and 200-day—indicating sustained bearish momentum.

Investor participation has also waned, with delivery volumes on 08 Jan dropping 23.35% against the five-day average, suggesting reduced buying interest. However, liquidity remains adequate for trades up to ₹1.71 crore based on recent average traded value.

Fundamental Challenges Weighing on the Stock

Despite some positive long-term indicators such as operating profit growth at an annual rate of 23.29%, the company’s financial health is under strain. The return on capital employed (ROCE) stands at a modest 2.7%, and the enterprise value to capital employed ratio of 2.2 suggests a fair valuation. However, the stock trades at a discount relative to its peers’ historical valuations, reflecting market scepticism.

More concerning are the company’s deteriorating profitability and debt servicing capacity. Over the past year, profits have plunged by 158.7%, with quarterly results for September 2025 revealing a pre-tax loss (excluding other income) of ₹111.78 crore, a 340% decline compared to the previous four-quarter average. Net profit after tax fell even more sharply by 613.2% to a loss of ₹99.22 crore, while net sales dropped 10.5% to ₹2,043.72 crore in the same period.

The company’s ability to manage its debt is limited, with a high Debt to EBITDA ratio of 3.83 times, signalling elevated leverage and financial risk. Additionally, the average return on equity is a mere 0.32%, indicating very low profitability relative to shareholders’ funds. Net sales growth over the last five years has been modest at 9.15% annually, further underscoring subdued long-term growth prospects.

Institutional investors hold a significant 45.17% stake, which typically reflects confidence in fundamentals. However, the recent negative earnings and weak stock performance suggest these investors may be cautious or awaiting clearer signs of recovery.

Conclusion: Why the Stock Is Falling

Piramal Pharma Ltd’s recent share price decline is primarily driven by weak quarterly financial results, poor profitability, and high leverage, which have eroded investor confidence. The stock’s consistent underperformance relative to the Sensex and its sector, combined with falling investor participation and trading below all major moving averages, reinforce the bearish outlook.

While the company shows some long-term operating profit growth and fair valuation metrics, these positives are overshadowed by significant losses, declining sales, and a challenging debt profile. The market’s reaction reflects concerns over the company’s ability to generate sustainable returns and service its debt obligations effectively.

Investors should closely monitor upcoming earnings and operational developments to assess whether the company can reverse its downward trajectory or if the current weakness will persist.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →